Myeloma, MultipleFLUCIPETNCT03966443
Fluciclovine PET/CT in Multiple Myeloma Patients
An observational study of Myeloma, Multiple and PET-CT, run by Oslo University Hospital at 1 site in Norway.
Trial summary
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myeloma, Multiple, PET-CT
- How many people
- 10 participants
- Where
- 1 siteNorway
- Study dates
- 1 Mar 2019to 31 Jan 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Multiple myeloma patients
Who may be able to join
- Multiple myeloma patients suitable for ASCT treatment
Who cannot join
- Patients with contraindications to ASCT treatment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Norway1 site, 1 recruiting
- Recruiting
Oslo University Hosptal
Oslo, 0424
Mona-Elisabeth Revheim, MD
About this study
Official title: PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose
Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients
- Conditions
- Myeloma, Multiple, PET-CT
- Medical subject headings
- Multiple Myeloma
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparing of image findings at PET
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2019
- Study start1 Mar 2019
- Primary completion31 Jan 2020 (estimated)
- Study completion31 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myeloma, MultipleStudies of the same condition, open and under way.
- More trials run by Oslo University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oslo University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mona-Elisabeth Revheim, Oslo University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03966443
- Sponsor's protocol ID
- 2018/2212/REK
- Acronym
- FLUCIPET
- Status last verified
- May 2019
- First submitted
- 27 May 2019
- Last updated
- 30 May 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No